Why is approval the real bottleneck, not the creative work?
Because a claim that would be a minor wording choice in most industries can carry real regulatory and liability weight in healthcare, and the review process exists specifically to catch that before it’s published rather than after. Writing an ad or a landing page is fast. Confirming that every claim on it is substantiated, correctly qualified, and consistent with what a specific practice, product or provider is actually licensed to say is the part that takes real time. And it should, because the cost of getting it wrong is genuinely higher here than in most categories.
The reviewers doing that check are often not marketing people at all: compliance officers, legal counsel, sometimes a medical director, reviewing marketing copy as one part of a much broader job. That’s the specific reason turnaround is slower than a typical marketing sign-off: the review queue is competing with clinical and legal priorities that reasonably come first.
What are the specific review stages that add time?
Claims substantiation is usually the slowest. Every specific claim about efficacy, outcomes or comparison to an alternative needs a documented basis before it can ship, and finding or confirming that basis often means going back to a clinical source rather than the marketing team’s own knowledge. Regulatory qualification review checks whether required disclaimers, licensing language or scope-of-practice qualifiers are present and correctly worded, a step with essentially no equivalent in most other industries’ marketing review.
Legal or risk review is a separate pass in many organisations, checking liability exposure distinct from the compliance question. The two overlap but aren’t the same review, and treating them as one step in a project timeline is a common planning mistake. Finally, a medical or clinical sign-off is sometimes required specifically to confirm accuracy of any health claim, which is a genuinely different skill set from the compliance and legal reviews and often sits with a different, busier person.
How do you actually plan a campaign around this honestly?
Build the review cycle into the project timeline as its own named phase with its own buffer, rather than folding it into “final approval” as an afterthought at the end. A launch date set without accounting for a multi-stage review queue is a launch date that’s likely to slip, and slipping under external pressure (an event date, a seasonal window) is a worse position than planning the buffer in from the start.
Front-load anything that needs clinical input. Claims that will need a clinical source or a medical sign-off should be identified and routed for review as early as possible in the project, in parallel with creative development. The alternative is discovering them during the final review pass, when the creative is otherwise finished and every day of delay is now visible and pressured. That sequencing difference alone is usually the single biggest lever on total project timeline, more than any change to the creative work itself, which is exactly why the “what changes by sector” section of our Healthcare page treats compliance planning as a distinct workstream rather than a checklist item.
What does a practical way to track claims through the review chain look like?
The simplest version that actually works is a claim-level log, separate from the general project tracker: one row per specific claim in the campaign, not one row per asset. A single landing page might carry six distinct claims, each potentially needing a different reviewer and a different evidence source; tracking approval at the page level rather than the claim level is how a genuinely approved page still ends up with one unapproved sentence nobody separately signed off on.
Each row wants four things: the exact claim as written, the evidence or source backing it, who’s reviewing it, and its current status. That last field matters more than it sounds: “pending” and “approved with edits” and “rejected, needs rewrite” are different states requiring different next actions. A tracker that only distinguishes “done” from “not done” hides exactly the information a project lead needs to know whether a launch date is actually at risk.
The payoff of tracking at this granularity is that a launch decision becomes a simple query: how many claims are still unresolved, and which specific ones, rather than a judgment call based on how the review “feels” to be going. That’s a small process investment that pays for itself the first time a launch date is genuinely on the line. It is the same discipline as a review checkpoint in an automated workflow: the approval sits at the point where a mistake would be public and hard to undo.
